Deep brain stimulation linked to longer survival for Parkinson's patients

December 21, 2017 by Tristan Horrom, Veterans Affairs Research
Richard Hutton, a patient at the Parkinson's Disease Research, Education, and Clinical Center at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, underwent deep brain stimulation back in 2009. Here, he gets checked by Dr. Meredith Spindler. Credit: Tommy Leonardi

A treatment called deep brain stimulation (DBS) could extend the life of people with Parkinson's disease. Researchers at the Edward Hines, Jr. VA Hospital in Illinois found that patients who received stimulation via an implanted device had a modest survival advantage compared with those treated with medication only.

The results appeared in the Nov. 18, 2017, issue of Movement Disorders.

Previous studies have shown that DBS can improve motor function in people with Parkinson's disease. The treatment involves electrodes surgically inserted into specific areas of the brain. An impulse generator battery—similar to what is used in pacemakers—is also implanted, under the collarbone or in the abdomen. The battery creates electrical impulses that the electrodes deliver to the brain tissue.

Dr. Frances Weaver, lead author on the study, explained the benefit of DBS: "Overall, DBS surgery has been viewed quite positively by both patients and providers. There is an immediate effect on patients who have DBS on their motor function—the dyskinesia [involuntary muscle movements] is either gone or greatly reduced. The patient can move around and do things they hadn't been able to."

While deep brain stimulation may improve function compared with those who do not receive it, little evidence exists on whether the treatment has any benefits to life expectancy. To answer that question, the researchers looked at data for 611 Veterans with Parkinson's disease who had a deep brain stimulation device implanted. They compared this with data on 611 Veterans with Parkinson's but without the device. The data came from VA and Medicare administrative files from between 2007 and 2013.

The researchers found that patients treated with deep brain stimulation survived an average of 6.3 years after the surgery, versus 5.7 years for the non-DBS patients after the date they might have gotten surgery based on their match to a surgery patient—a difference of eight months. The researchers had paired each DBS patient with a clinically and demographically similar non-DBS patient—for example, in terms of age and symptom severity—and tracked survival from the date when surgery either took place, for the DBS group; or might have theoretically taken place, for the non-DBS group.

The average age of veterans in the study was 69, reflecting the higher prevalence of Parkinson's among older people. The older age of the study group could have led to more deaths from age-related conditions, but the researchers point out that a majority of the causes of death for those who died during the study period were related to Parkinson's disease.

While the survival edge in the DBS group is modest, the researchers point out that quality of life is also improved following DBS, mostly because the treatment can help control symptoms such as tremors and rigidity.

While the results suggest that deep brain stimulation could improve survival rates for patients with Parkinson's disease, the researchers note a few limitations to the study. They explain that it is possible that patients were healthier than their counterparts in the medication-only group. Patients with the implanted surgical device were more likely to have been monitored closely, so other chronic conditions may have been diagnosed and treated earlier. The study group was also mostly male—because the veteran population is majority male—meaning that the results cannot necessarily be generalized to women with Parkinson's disease.

Parkinson's disease is a neurodegenerative disorder. It affects neurons in the brain that produce dopamine. Its cause is currently unknown, and so far there is no cure. Parkinson's itself is not fatal, but complications related to the disease often lead to death. Common symptoms of Parkinson's disease include tremor, slowness of movement, limb rigidity, and walking and balance problems. People with Parkinson's disease have a shorter life expectancy than those without the disease.

While medication can manage symptoms of the disease, it has not been shown to improve survival for those with Parkinson's. As Weaver explains, patients usually undergo DBS surgery when the medication is no longer effective. "The surgery may get patients back to where they were when the medication was effective. That is, DBS is typically as effective as the medication—if the medication was still working," she says.

The researchers believe that more research is warranted into whether DBS can extend in Parkinson's disease. It remains unclear whether the treatment modifies the actual , or just helps control the related conditions that may shorten life. According to Weaver, the improved quality of life after DBS may improve survival. It is also possible that the ongoing monitoring required with DBS means that are getting more medical attention in general, leading to better care. More research is needed to see what direct effect DBS has on neuroplasticity or function.

Explore further: DBS safe but not beneficial in parkinson's dementia

Related Stories

DBS safe but not beneficial in parkinson's dementia

December 19, 2017
(HealthDay)—Low-frequency deep brain stimulation of the nucleus basalis of Meynert (NBM DBS) can be safely conducted in patients with Parkinson's disease dementia, but it does not result in significant improvements in primary ...

Rush testing if genetic clues identify best candidates for Parkinson's surgery

September 1, 2017
In the first ever clinical investigation involving genetic screening for Parkinson's disease, researchers are testing whether the presence of a specific genetic mutation identifies which patients are the best candidates for ...

FDA approves brain stimulation device for Parkinson's disease

June 14, 2015
(HealthDay)—The U.S. Food and Drug Administration on Friday approved a device that can be implanted into the brain to help people battling Parkinson's disease.

Less-invasive method of brain stimulation helps patients with Parkinson's disease

October 16, 2012
Electrical stimulation using extradural electrodes—placed underneath the skull but not implanted in the brain—is a safe approach with meaningful benefits for patients with Parkinson's disease, reports the October issue ...

Individualizing deep brain stimulation in patients with Parkinson's disease

June 23, 2017
Working with colleagues from Harvard Medical School and Würzburg, researchers from Charité - Universitätsmedizin Berlin have been examining the use of deep brain stimulation in the treatment of Parkison's disease in an ...

Recommended for you

Parkinson's gene initiates disease outside of the brain

March 21, 2018
Until very recently, Parkinson's had been thought a disease that starts in the brain, destroying motion centers and resulting in the tremors and loss of movement. New research published this week in the journal Brain, shows ...

Faulty cellular membrane 'mix' linked to Parkinson's disease

March 15, 2018
Working with lab-grown human brain cells, Johns Hopkins researchers report they have uncovered a much sought-after connection between one of the most common genetic mutations in Parkinson's disease and the formation of fatty ...

Researchers uncover culprit in Parkinson's brain cell die-off

March 5, 2018
An estimated 10 million people worldwide are living with Parkinson's disease—an incurable neurodegenerative disorder that leads to an increasing loss of motor control.

Study uncovers cause of cell death in Parkinson's disease

February 26, 2018
A University of Guelph researcher has discovered one of the factors behind nerve cell death in Parkinson's disease, unlocking the potential for treatment to slow the progression of this fatal neurodegenerative disorder.

Protein levels in spinal fluid correlate to posture and gait difficulty in Parkinson's

February 21, 2018
Levels of a protein found in the brain called alpha-synuclein (α-syn) are significantly lower than normal in cerebrospinal fluid collected in Parkinson's disease patients suffering from postural instability and gait difficulty, ...

Calcium may play a role in the development of Parkinson's disease

February 19, 2018
Researchers have found that excess levels of calcium in brain cells may lead to the formation of toxic clusters that are the hallmark of Parkinson's disease.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.